Abstract
In a general practice population of 57 000, 32 patients suffering from Parkinson's disease were identified from repeat prescription indexes and direct questioning of all members of the primary health care team. Of these patients 26 were receiving an L-dopa preparation and 10 an anticholinergic drug. The only newer drug found to be in use was bromocriptine and three patients were receiving this treatment.
Of the 26 patients receiving an L-dopa preparation one received L-dopa alone, six L-dopa with benserazide (Madopar, Roche) and 19 L-dopa with carbidopa (Sinemet, Merck, Sharp and Dohme). The patients treated with Sinemet were receiving inadequate doses of carbidopa - three quarters received less than 75 mg per day which was in part a reflection of the low doses of L-dopa the patients received, the average dose being 468 mg per day. The L-dopa preparations were given in adequately spaced doses.
The general practitioner made the diagnosis in 20 of the 32 cases and was in control of the drug therapy in 15 cases, however 25 cases were referred for specialist advice.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boshes B. Sinemet and the treatment of Parkinsonism. Ann Intern Med. 1981 Mar;94(3):364–370. doi: 10.7326/0003-4819-94-3-364. [DOI] [PubMed] [Google Scholar]
- EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
- Godwin-Austen R. B., Smith N. J. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1977 May;40(5):479–482. doi: 10.1136/jnnp.40.5.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoehn M. M. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. Arch Neurol. 1980 Mar;37(3):146–149. doi: 10.1001/archneur.1980.00500520044006. [DOI] [PubMed] [Google Scholar]
- Kent S. Assessing L-dopa therapy for Parkinson's. Geriatrics. 1981 Apr;36(4):34–43. [PubMed] [Google Scholar]
- Rinne U. K., Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979 Dec;29(12):1584–1589. doi: 10.1212/wnl.29.12.1584. [DOI] [PubMed] [Google Scholar]
- Rinne U. K. Recent advances in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1980;78:103–121. doi: 10.1111/j.1600-0404.1980.tb05430.x. [DOI] [PubMed] [Google Scholar]
- Teychenne P. F., Bergsrud D., Racy A., Elton R. L., Vern B. Bromocriptine: low-dose therapy in Parkinson disease. Neurology. 1982 Jun;32(6):577–583. doi: 10.1212/wnl.32.6.577. [DOI] [PubMed] [Google Scholar]
- Weiner M. Update on antiparkinsonian agents. Geriatrics. 1982 Sep;37(9):81-4, 89-91. [PubMed] [Google Scholar]